Brinson Patrick

In a note released Tuesday, Brinson Patrick Initiated coverage on MannKind (NASDAQ: MNKD) at Market Outperform and announced a $12 price target. Brinson Patrick analyst Christopher James emphasized the expected FDA approval of the diabetes drug Afrezza as the main driver for MannKind's Outperform...

In a report published Monday, Brinson Patrick analyst Vernon Bernardino initiated coverage on Vical (NASDAQ: VICL) with a Market Outperform rating and $7.00 price target. In the report, Brinson Patrick noted, “We are initiating coverage of Vical with a Market Outperform rating and 12-month...

In a report published Wednesday, Brinson Patrick analyst Vernon Bernardino downgraded the rating on ZIOPHARM Oncology (NASDAQ: ZIOP) from Market Outperform to Market Perform, and lowered the price target from $7.00 to $1.50. In the report, Bernardino noted, “Earlier today, ZIOPHARM announced...

In a report published Monday, Brinson Patrick reiterated its Market Outperform rating and $3.00 price target on Novavax (NASDAQ: NVAX). Brinson Patrick noted, “Novavax Inc. (NVAX) has three vaccine candidates in active evaluation in four different therapeutic indications and a fourth candidate...

In a report published Thursday, Brinson Patrick initiates coverage on NeoStem (NYSE: NBS) with a Market Outperform and $6 price target. In the report Brinson Patrick wrote, "NeoStem is developing an active portfolio of product candidate assets based on the company's diverse array of technology...

Brinson Patrick initiated coverage on Zogenix (NASDAQ: ZGNX) with a Market Outperform rating and a $5.00 price target. Brinson Patrick commented, "Given the number of issues surrounding the FDA's decision on Zohydro ER's approval, we had suspected the FDA would take actions that would put Zohydro...

In a report published Monday, Brinson Patrick initiated coverage on MannKind Corporation (NASDAQ: MNKD) with a Market Outperform rating and $6.00 price target. Brinson Patrick noted, “MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their...